Kazuhiro Ueda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuhiro Ueda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Kimikazu Hamano
Department of Surgery and Clinical Science, Division of Chest Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
5 shared publicationsToshiki Tanaka
Department of Surgery and Clinical Science, Division of Chest Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
4 shared publicationsKazuyoshi Suga
First Department of Surgery and Department of Radiology Yamaguchi University School of Medicine Ube Yamaguchi Japan
2 shared publicationsMasataro Hayashi
Yamaguchi University Graduate School of Medicine
2 shared publicationsNobuyuki Tanaka
Yamaguchi University Graduate School of Medicine
2 shared publications- Tao-Sheng Li
Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
2 shared publications
Latest Publications
- Open Access
- 10 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1231
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
We evaluated the safety and efficacy of induction chemotherapy with bevacizumab followed by maintenance chemotherapy with bevacizumab for advanced non-small cell lung cancer (NSCLC) in this multicenter phase II study. Chemotherapy-naïve patient with stage IIIB–IV or recurrent nonsquamous NSCLC were eligible. We planned approximately four cycles of induction cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and bevacizumab (15 mg/kg) followed by maintenance with pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) until disease progression. Progression-free survival (PFS) was the primary endpoint. Forty patients received a median of four induction chemotherapy cycles. Of them, 35 (87.5%) patients received a median of nine maintenance chemotherapy cycles. The objective response was 70.6%, and the disease control rate was 97.1%. The median PFS was 10.8 (95% CI, 9.0–12.6), and overall survival was 48.0 (95% CI, 32.9–63.1) months. Median PFS of 23 patients with epidermal growth factor receptor (EGFR) mutations and of 16 patients without EGFR mutations were 12.9 (95% CI, 9.4–16.3) and 7.9 (95% CI, 1.1–14.7) months, respectively. Toxicities graded ≥3 included neutropenia (15%), anemia (15%), hypertension (7.5%), anorexia (7.5%), fatigue (7.5%), thromboembolic events (5%), jaw osteonecrosis (5%), nausea (2.5%), oral mucositis (2.5%), tumor pain (2.5%), hyponatremia (2.5%), and gastrointestinal perforation (2.5%). Treatment-related deaths were not found. In patients with advanced or recurrent nonsquamous NSCLC, induction chemotherapy with cisplatin, pemetrexed, and bevacizumab followed by maintenance chemotherapy with pemetrexed and bevacizumab is safe and effective regardless of their EGFR mutation status. UMIN Clinical Trial Registry: UMIN000005569 . Registered date: May 8, 2011.
- 10 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1231
Open AccessMulticenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
We evaluated the safety and efficacy of induction chemotherapy with bevacizumab followed by maintenance chemotherapy with bevacizumab for advanced non-small cell lung cancer (NSCLC) in this multicenter phase II study. Chemotherapy-naïve patient with stage IIIB–IV or recurrent nonsquamous NSCLC were eligible. We planned approximately four cycles of induction cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and bevacizumab (15 mg/kg) followed by maintenance with pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) until disease progression. Progression-free survival (PFS) was the primary endpoint. Forty patients received a median of four induction chemotherapy cycles. Of them, 35 (87.5%) patients received a median of nine maintenance chemotherapy cycles. The objective response was 70.6%, and the disease control rate was 97.1%. The median PFS was 10.8 (95% CI, 9.0–12.6), and overall survival was 48.0 (95% CI, 32.9–63.1) months. Median PFS of 23 patients with epidermal growth factor receptor (EGFR) mutations and of 16 patients without EGFR mutations were 12.9 (95% CI, 9.4–16.3) and 7.9 (95% CI, 1.1–14.7) months, respectively. Toxicities graded ≥3 included neutropenia (15%), anemia (15%), hypertension (7.5%), anorexia (7.5%), fatigue (7.5%), thromboembolic events (5%), jaw osteonecrosis (5%), nausea (2.5%), oral mucositis (2.5%), tumor pain (2.5%), hyponatremia (2.5%), and gastrointestinal perforation (2.5%). Treatment-related deaths were not found. In patients with advanced or recurrent nonsquamous NSCLC, induction chemotherapy with cisplatin, pemetrexed, and bevacizumab followed by maintenance chemotherapy with pemetrexed and bevacizumab is safe and effective regardless of their EGFR mutation status. UMIN Clinical Trial Registry: UMIN000005569 . Registered date: May 8, 2011.
- 1 October 2018
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 106 (4) , e215-e218
Use of Stitching and Bioabsorbable Mesh and Glue to Combat Prolonged Air Leaks
- 1 October 2018
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 106 (4) , e215-e218
Use of Stitching and Bioabsorbable Mesh and Glue to Combat Prolonged Air Leaks
- 23 November 2013
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 62 (1) , 24-30
Long-term pulmonary function after major lung resection
The function of the remaining lungs after major lung resection may be a determinant of the early postoperative outcome, as well as the late postoperative quality of life of the patient. Thus, extensive efforts have been made to accurately estimate the postoperative pulmonary function using a variety of methods: the segment counting method is utilized in patients without parenchymal diseases, while the functional lung imaging technique may be useful in patients with heterogeneous anatomical lung diseases. The postoperative pulmonary function is influenced not only by the extent of parenchymal resection, but also by various other factors, such as the site of resection, the mode of thoracotomy, the severity of pulmonary emphysema and/or the postoperative progression of pulmonary fibrosis. Although thoracoscopic surgery or segmental resection can lessen the extent of chest wall damage or the extent of parenchymal resection compared with conventional operations, the resulting functional benefits do not last. Interestingly, the postoperative pulmonary function continues to improve during the first postoperative year as if the remaining lungs grow, although the cause(s) of this compensatory response of the remaining lungs remains unclear. Such an ability of the remaining lung to compensate for the lost lung function may eventually determine the late postoperative pulmonary function.
- 23 November 2013
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 62 (1) , 24-30
Long-term pulmonary function after major lung resection
The function of the remaining lungs after major lung resection may be a determinant of the early postoperative outcome, as well as the late postoperative quality of life of the patient. Thus, extensive efforts have been made to accurately estimate the postoperative pulmonary function using a variety of methods: the segment counting method is utilized in patients without parenchymal diseases, while the functional lung imaging technique may be useful in patients with heterogeneous anatomical lung diseases. The postoperative pulmonary function is influenced not only by the extent of parenchymal resection, but also by various other factors, such as the site of resection, the mode of thoracotomy, the severity of pulmonary emphysema and/or the postoperative progression of pulmonary fibrosis. Although thoracoscopic surgery or segmental resection can lessen the extent of chest wall damage or the extent of parenchymal resection compared with conventional operations, the resulting functional benefits do not last. Interestingly, the postoperative pulmonary function continues to improve during the first postoperative year as if the remaining lungs grow, although the cause(s) of this compensatory response of the remaining lungs remains unclear. Such an ability of the remaining lung to compensate for the lost lung function may eventually determine the late postoperative pulmonary function.
- 8 May 2012
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 60 (6) , 363-366
Left upper lobectomy with combined resection of the distal arch aorta after chemoradiotherapy for locally advanced lung cancer
We report a case of complete resection of lung cancer involving the thoracic aorta, after induction chemoradiotherapy in a 55-year-old man. The chemoradiotherapy, which consisted of two courses of platinum-based chemotherapy with concurrent radiation to a total of 40 Gy, resulted in a partial response. Left upper lobectomy with combined resection and reconstruction of the distal arch aorta and left subclavian artery was performed under cardiopulmonary bypass. The patient was given two courses of platinum-based adjuvant chemotherapy, and there has been no sign of recurrence in the 34 months since his operation.
- 8 May 2012
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 60 (6) , 363-366
Left upper lobectomy with combined resection of the distal arch aorta after chemoradiotherapy for locally advanced lung cancer
We report a case of complete resection of lung cancer involving the thoracic aorta, after induction chemoradiotherapy in a 55-year-old man. The chemoradiotherapy, which consisted of two courses of platinum-based chemotherapy with concurrent radiation to a total of 40 Gy, resulted in a partial response. Left upper lobectomy with combined resection and reconstruction of the distal arch aorta and left subclavian artery was performed under cardiopulmonary bypass. The patient was given two courses of platinum-based adjuvant chemotherapy, and there has been no sign of recurrence in the 34 months since his operation.
- 1 March 2004
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (3) , 1033-1037
Preoperative imaging of the lung sentinel lymphatic basin with computed tomographic lymphography: a preliminary study
- 1 March 2004
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (3) , 1033-1037
Preoperative imaging of the lung sentinel lymphatic basin with computed tomographic lymphography: a preliminary study
- 29 February 2004
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (2) , 426-430
Radioisotope lymph node mapping in nonsmall cell lung cancer: can it be applicable for sentinel node biopsy?
- 29 February 2004
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (2) , 426-430
Radioisotope lymph node mapping in nonsmall cell lung cancer: can it be applicable for sentinel node biopsy?